IBI112 for adolescents with moderate to severe plaque psoriasis
Official title: A Phase Ⅰ/Ⅲ Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Picankibart in Adolescent Patients With Moderate to Severe Plaque Psoriasis
Run by Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. · NCT07265284 · Data updated 2026-11-12
This trial will test whether the drug IBI112 can improve skin symptoms and is safe for adolescents aged 12–18 who have moderate to severe plaque psoriasis compared with a placebo.
Quick facts
| Phase | Phase 3 |
|---|---|
| Study type | Interventional |
| Ages | 12 Years to 18 Years |
| Sex | All |
| Enrollment | 104 (estimated) |
| Sponsor | Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. Industry-sponsored |
| Locations | 1 site (Beijing, Beijing Municipality) |
| Status | Recruiting |
| Started | December 3, 2025 |
| Main results expected | September 30, 2026 |
| Study ends | January 31, 2029 |
| Registry record updated | December 22, 2025 |
| Trial ID | NCT07265284 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adolescents aged 12 to 18 with a confirmed history of plaque psoriasis for at least 6 months who are suitable for phototherapy and/or systemic treatment are the intended participants.
✕Probably not a fit
Patients with erythrodermic, pustular, medication-induced psoriasis, new-onset guttate psoriasis, recent IL-17 or TNF-alpha targeted therapy, or uncontrolled serious medical conditions are unlikely to be eligible or benefit from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a Phase 3 interventional trial sponsored by Innovent Biopharmaceuticals conducted at Beijing Children's Hospital for adolescents with moderate to severe plaque-type psoriasis. Eligible participants aged 12–18 with at least a 6-month history of psoriasis will receive either IBI112 or a matching placebo and be followed over the treatment period. The protocol excludes those with certain psoriasis subtypes, recent targeted biologic therapy, or uncontrolled serious medical conditions. Efficacy will be measured by dermatologic outcomes and safety will be monitored through regular clinic visits and adverse event reporting.
Why it matters
Potential benefit: If successful, IBI112 could reduce psoriasis symptoms and improve quality of life for adolescents with moderate to severe plaque psoriasis.
How similar studies have gone: Other biologic therapies targeting inflammatory pathways have shown strong results in adolescents with moderate to severe plaque psoriasis, so this approach builds on existing successful strategies though IBI112 itself is a novel agent.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: Males or females aged 12 to 18 years; Diagnosed with plaque psoriasis and a history of psoriasis ≥6 months; suitable for phototherapy and/or systemic treatment for psoriasis. Exclusion Criteria: History of or current signs or symptoms of severe, progressive, or uncontrolled renal, hepatic, hematological, gastrointestinal, endocrine, pulmonary, cardiac, neurologic, cerebral, or psychiatric disease Participant has history of erythrodermic psoriasis, generalized or localized pustular psoriasis, medication-induced or medication-exacerbated psoriasis, or new onset guttate psoriasis Has received any therapeutic agent directly targeted to IL-17within 6 months of the first administration of study agent Has received any therapeutic agent directly targeted toTNF-a within 3 months of the first administration of study agent Has received any conventional therapeutic agent within 1 months of the first administration of study agent Has received any topic therapeutic agent within 2 weeks of the first administration of study agent Hsa received IBI112
Where it's running
-
Beijing Children's Hospital Affiliated to Capital Medical University
Beijing, Beijing Municipality, China Recruiting
Study contacts
- Study coordinator: Bingjing Feng
- Email: bingjing.feng@innoventbio.com
- Phone: +86 18361923769
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
HB0017 Injection safety and PK in low-weight adults at different injection sites
This early-phase study tests a single subcutaneous HB0017 injection in healthy, low-weight adults and compares how the body processes the drug when injected at different sites.
-
MK-8644: first-in-human test in healthy people and people with psoriasis
This early-phase study tests MK-8644 versus placebo in healthy volunteers and people with psoriasis to see if it is safe and tolerable.
-
Is XJH05 Ointment Effective for Plaque Psoriasis?
This study tests whether the XJH05 ointment can help people with plaque psoriasis compare to a calcipotriol ointment.
-
Guselkumab after Ustekinumab in adults with moderate-to-severe psoriasis in routine care
This study looks at how well guselkumab works for people with moderate-to-severe psoriasis after switching from ustekinumab in everyday clinical practice.
-
TQH3906 capsules vs warmer options in adults with moderate to severe plaque psoriasis
This Phase 3 trial tests whether once-daily TQH3906 capsules can help adults with moderate to severe plaque psoriasis better than a placebo or the active drug deucravacitinib.
-
SHR-1139 injectable treatment for adults with plaque psoriasis
This study tests whether an SHR-1139 injection works and is safe for adults with plaque psoriasis.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.